160 related articles for article (PubMed ID: 32146725)
1. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression.
Shigeoka T; Nomiyama T; Kawanami T; Hamaguchi Y; Horikawa T; Tanaka T; Irie S; Motonaga R; Hamanoue N; Tanabe M; Nabeshima K; Tanaka M; Yanase T; Kawanami D
J Diabetes Investig; 2020 Sep; 11(5):1137-1149. PubMed ID: 32146725
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
Nomiyama T; Kawanami T; Irie S; Hamaguchi Y; Terawaki Y; Murase K; Tsutsumi Y; Nagaishi R; Tanabe M; Morinaga H; Tanaka T; Mizoguchi M; Nabeshima K; Tanaka M; Yanase T
Diabetes; 2014 Nov; 63(11):3891-905. PubMed ID: 24879833
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation.
Iwaya C; Nomiyama T; Komatsu S; Kawanami T; Tsutsumi Y; Hamaguchi Y; Horikawa T; Yoshinaga Y; Yamashita S; Tanaka T; Terawaki Y; Tanabe M; Nabeshima K; Iwasaki A; Yanase T
Endocrinology; 2017 Dec; 158(12):4218-4232. PubMed ID: 29045658
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor activation by liraglutide promotes breast cancer through NOX4/ROS/VEGF pathway.
Liu ZZ; Duan XX; Yuan MC; Yu J; Hu X; Han X; Lan L; Liu BW; Wang Y; Qin JF
Life Sci; 2022 Apr; 294():120370. PubMed ID: 35124000
[TBL] [Abstract][Full Text] [Related]
5. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
6. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.
Yue Y; Xu Y; Huang L; Pan D; Bai Z; Wang L; Yang R; Yan J; Song H; Li X; Yang M
Anticancer Agents Med Chem; 2019; 19(4):509-514. PubMed ID: 30068284
[TBL] [Abstract][Full Text] [Related]
8. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner.
Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T
Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389
[TBL] [Abstract][Full Text] [Related]
9. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
10. Exendin-4 enhances radiation response of prostate cancer.
He W; Li J
Prostate; 2018 Nov; 78(15):1125-1133. PubMed ID: 30009503
[TBL] [Abstract][Full Text] [Related]
11. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
12. Increased co-expression of PSMA2 and GLP-1 receptor in cervical cancer models in type 2 diabetes attenuated by Exendin-4: A translational case-control study.
Mao D; Cao H; Shi M; Wang CC; Kwong J; Li JJX; Hou Y; Ming X; Lee HM; Tian XY; Wong CK; Chow E; Kong APS; Lui VWY; Chan PKS; Chan JCN
EBioMedicine; 2021 Mar; 65():103242. PubMed ID: 33684886
[TBL] [Abstract][Full Text] [Related]
13. Exendin-4 does not modify growth or apoptosis of human colon cancer cells.
Wenjing H; Shuang Y; Weisong L; Haipeng X
Endocr Res; 2017 Aug; 42(3):209-218. PubMed ID: 28318339
[TBL] [Abstract][Full Text] [Related]
14. Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Tsutsumi Y; Nomiyama T; Kawanami T; Hamaguchi Y; Terawaki Y; Tanaka T; Murase K; Motonaga R; Tanabe M; Yanase T
PLoS One; 2015; 10(10):e0139709. PubMed ID: 26439622
[TBL] [Abstract][Full Text] [Related]
15. Indirectly radioiodinated exendin-4 as an analytical tool for in vivo detection of glucagon-like peptide-1 receptor in a disease setting.
Kondo N; Oishi A; Hirata M; Temma T
Ann Nucl Med; 2021 Jan; 35(1):83-91. PubMed ID: 33067731
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 inhibits glioma cell migration, invasion and epithelial-to-mesenchymal transition through GLP-1R/sirt3 pathway.
Nie ZJ; Zhang YG; Chang YH; Li QY; Zhang YL
Biomed Pharmacother; 2018 Oct; 106():1364-1369. PubMed ID: 30119208
[TBL] [Abstract][Full Text] [Related]
17. Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
Kanda R; Hiraike H; Wada-Hiraike O; Ichinose T; Nagasaka K; Sasajima Y; Ryo E; Fujii T; Osuga Y; Ayabe T
BMC Cancer; 2018 Jun; 18(1):657. PubMed ID: 29907137
[TBL] [Abstract][Full Text] [Related]
18. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
Zhao HJ; Jiang X; Hu LJ; Yang L; Deng LD; Wang YP; Ren ZP
J Mol Endocrinol; 2020 Feb; 64(2):103-113. PubMed ID: 31855560
[TBL] [Abstract][Full Text] [Related]
19. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
